David Milar
Pancreatic Ductal Adenocarcinoma is among the most lethal cancers, characterized by limited treatment options and poor prognosis. Its hallmark resistance to conventional therapies necessitates the exploration of targeted therapeutic approaches. Recent advances have significantly deepened our understanding of the oncogenic pathways driving PDAC development and progression. This article reviews clinical and preclinical strategies targeting these pathways, highlighting promising avenues for treating this deadly cancer.
Partagez cet article
English 
Spanish 
Chinese 
Russian 
German 
Japanese 
Portuguese 
Hindi 